CELEX: 62021TN0194
Language: en
Date: 2021-04-12 00:00:00
Title: Case T-194/21: Action brought on 12 April 2021 — Fidia farmaceutici v EUIPO — Stelis Biopharma (HYALOSTEL ONE)

7.6.2021   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 217/57
            
         
      Action brought on 12 April 2021 — Fidia farmaceutici v EUIPO — Stelis Biopharma (HYALOSTEL ONE)
      (Case T-194/21)
      (2021/C 217/72)
      Language of the case: English
      
         Parties
      
      
         Applicant: Fidia farmaceutici SpA (Abano Terme, Italy) (represented by: R. Kunz-Hallstein and H. Kunz-Hallstein, lawyers)
      
         Defendant: European Union Intellectual Property Office (EUIPO)
      
         Other party to the proceedings before the Board of Appeal: Stelis Biopharma ltd. (Karnataka, India)
      
         Details of the proceedings before EUIPO
      
      
         Proprietor of the trade mark at issue: Other party to the proceedings before the Board of Appeal
      
         Trade mark at issue: International registration designating the European Union in respect of the figurative HYALOSTEL ONE mark — International registration designating the European Union No 1 399 649
      
         Procedure before EUIPO: Opposition proceedings
      
         Contested decision: Decision of the Fifth Board of Appeal of EUIPO of 27 January 2021 in Case R 831/2020-5
      
         Form of order sought
      
      The applicant claims that the Court should:
      
                  —
               
               
                  annul the contested decision;
               
            
                  —
               
               
                  order EUIPO to pay the costs, in the alternative, if the other party before the Board of Appeal intervenes, order EUIPO and the intervener jointly and severally to pay the costs.
               
            
         Pleas in law
      
      
                  —
               
               
                  Infringement of Article 165(1) of Regulation (EU) 2017/1001 of the European Parliament and of the Council and Articles 32(f) and 39(5) of Commission Delegated Regulation (EU) 2018/625;
               
            
                  —
               
               
                  Infringement of the right to be heard and the obligation to state reasons pursuant Article 94(1) of Regulation (EU) 2017/1001 of the European Parliament and of the Council;
               
            
                  —
               
               
                  Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council.